IVD Companies Consider Reimbursement, Regulatory Implications Of ASR Reg
This article was originally published in The Gray Sheet
Executive Summary
Companies that market analyte-specific reagents may need to educate third-party payers to avoid reimbursement rejection, Jeffrey Gibbs, an attorney with the Washington, D.C. law firm of Hyman, Phelps and McNamara told industry attendees at a Dec. 7 Barnett International in-vitro diagnostics conference.